<DOC>
	<DOCNO>NCT01842321</DOCNO>
	<brief_summary>The purpose study estimate antitumour activity abiraterone acetate Patients Molecular Apocrine HER2-negative locally advance metastatic Breast Cancer .</brief_summary>
	<brief_title>Abiraterone Acetate Molecular Apocrine Breast Cancer</brief_title>
	<detailed_description>Screening : All woman 18+ , confirm locally advanced metastatic Triple Negative Breast Cancer ( TNBC ) , screen invite participate ( 300-500 patient ) . Only patient centralize confirmation ER-/PR-/HER2- evaluation AR+ include treat abiraterone acetate plus prednisone ( 31 patient ) . The Treatment phase comprise series 4 weeks-cycles continuous study treatment . Study drug treatment continue early follow event : disease progression , unacceptable toxicity , death . At disease progression , patient must discontinue study drug evaluate within 30 day Post treatment visit enter Follow-Up phase.Patients enter Follow-Up Period regardless reason study drug discontinuation monitor every 3 month ( ± 7 day ) 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Women age ≥ 18 year ; Histologically confirm locally advance metastatic breast cancer ; Triple negative breast cancer : Estrogen receptor ( ER ) negative Progesterone receptor ( PR ) negative , define &lt; 10 % tumour stain cell immunohistochemistry ( IHC ) ; HER2 negative status ( i.e . IHC score 0 1+ , IHC score 2+ FISH/SISH/CISH negative ) , confirm centrally inclusion FFPE tissue either primary metastatic breast cancer site* ; Androgen receptor ( AR ) positive , define centrally ≥ 10 % tumour stain cell IHC ( AR assessment local pathologist inclusion mandatory ) ; Patients could chemotherapy naïve ( provide present lifethreatening metastasis ) receive number previous line chemotherapy ( provide life expectancy ≥ 3 month ) ; Pre post menopausal patient eligible . Measurable non measurable disease accord RECIST v1.1 criterion ; PS ( ECOG ) ≤ 2 ; Normal haematological function : ANC ≥ 1,500/mm3 ; platelet count ≥ 100,000/mm3 ; haemoglobin &gt; 10 g/dl ; Normal hepatic function : total bilirubin ≤ 1.5 upper normal limit ( UNL ) ; ASAT ALAT ≤ 2.5 UNL ( ≤ 5 UNL presence liver metastasis ) ; Creatinine clearance ( MDRD formula ) ≥ 50 mL/min OR creatinine ≤ 1.5 time ULN ; Normal kalemia ( serum potassium ≥ 3.5 mM ) , natremia magnesemia ; Systolic blood pressure ( BP ) &lt; 160 mm Hg diastolic BP &lt; 95 mm Hg , documented inclusion day ( Hypertension baseline assessment allow provide currently control antihypertensive drug ) ; Cardiac ejection fraction ≥50 % measure MUGA ECHO do within 4 week inclusion ; If receive bisphosphonate denosumab , dose must stable least 2 dos inclusion ; Patient agree use effective contraception ≥ 6 month completion study treatment ; Patient able comply protocol ; Patient must sign write informed consent form prior study specific procedure ; Patient must affiliate Social Health Insurance . Male breast cancer ; HER2positive status ( positivity define IHC3+ and/or FISH amplification &gt; 2.2 ) ; Other concurrent malignancy , except adequately treat conebiopsied situ carcinoma cervix basal cell squamous cell carcinoma skin ; patient undergo potentially curative therapy prior malignancy eligible provide evidence disease ≥ 5 year patient deem low risk recurrence ; Active brain metastasis leptomeningeal disease ; History brain metastasis allow provided lesion stable least 3 month document head CT scan MRI brain ; Nonmalignant systemic disease , include active infection concurrent serious illness would make patient high medical risk ; Significant cardiovascular disease , include follow : 1 . NYHA class IIIIV congestive heart failure ; 2 . Unstable angina pectoris myocardial infarction within past 6 month ; 3 . Severe valvular heart disease ; 4 . Ventricular arrhythmia require treatment . Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption include ; Patients know allergy , hypersensitivity intolerance abiraterone acetate , prednisone , excipients ; Persistent toxicity ≥ grade 2 cause , except chemotherapyinduced alopecia Grade 2 peripheral neuropathy ; Active uncontrolled autoimmune disease require concurrent corticosteroid therapy ; Any gastrointestinal disorder interfere absorption study drug ; Difficulties swallow study capsule ; Prior anticancer therapy , include radiotherapy , endocrine therapy , immunotherapy , chemotherapy ( CT ) within last 3 week ( 2 week oral weekly CT ; 6 week nitrosoureas mitomycin C ) , investigational agent ; Concurrent palliative radiotherapy allow ; Concurrent enrolment another clinical trial investigational therapy administer ; Pregnant woman , woman likely become pregnant breastfeeding ; Patients psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial ; Patients history non compliance medical regimen unwilling unable comply protocol ; Individual deprive liberty place authority tutor .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>locally advanced</keyword>
	<keyword>metastatic</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Molecular Apocrine</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Abiraterone acetate</keyword>
</DOC>